Allogene Therapeutics (ALLO) Research & Development (2018 - 2026)

Allogene Therapeutics has disclosed Research & Development across 9 years of filings, most recently posting $32.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $32.0 million, down 36.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $132.0 million (down 30.64% YoY), and the FY2025 annual result was $150.2 million, down 21.92% from the prior year.
• Research & Development came in at $32.0 million for Q1 2026 at Allogene Therapeutics, up from $28.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $80.2 million in Q1 2023 to a low of $28.6 million in Q4 2025.
• The 5-year median for Research & Development is $50.4 million (2024), against an average of $51.4 million.
• Across the five-year window, Research & Development jumped 39.71% in 2022 and slumped 36.33% in 2025, its largest moves.
• Allogene Therapeutics' Research & Development stood at $75.4 million in 2022, then decreased by 27.52% to $54.7 million in 2023, then slipped by 17.73% to $45.0 million in 2024, then plunged by 36.33% to $28.6 million in 2025, then gained by 11.77% to $32.0 million in 2026.
• The last three Research & Development figures came in at $32.0 million (Q1 2026), $28.6 million (Q4 2025), and $31.2 million (Q3 2025), per Business Quant data.